Dendritic cell immunoreceptor (DCIR) deficiency is related to development of autoimmune disorders and DCIR gene polymorphisms are associated with rheumatoid arthritis (RA). We analyzed the mRNA expression from the four known transcripts of DCIR in IFN-g-treated human leukocytes together with fine mapping across the locus. RA patients and healthy controls were genotyped for several single nucleotide polymorphisms (SNPs) in DCIR and flanking regions. mRNA expression in peripheral blood mononuclear cells (PBMCs), stimulated with gamma-interferon (IFN-g) in vitro, was determined by transcript-specific PCR. Our data reveal that IFN-g significantly downregulates the average expression of transcripts DCIR_v1, DCIR_v2, DCIR_v3 and DCIR_v4 (Po0.0001 for v1, Po0.02 for v2, Po0.0001 for v3, Po0.001 for _v4, patients and controls, Wilcoxon signed-rank). The expression of DCIR showed significant association with variations in the gene. Cells with the RAassociated allele rs2024301 exhibit a significant increase in the expression of DCIR_v4. We also present a new fifth isoform lacking exons 2, 3 and 4. This data illustrate that common genetic variations may influence DCIR mRNA expression. We also show that the expression is regulated by the inflammatory mediator IFN-g, affecting all four transcripts and that this was independent of genotype.
Introduction
The dendritic cell immunoreceptor (DCIR) is in its fulllength form a membrane-bound protein with an immunoreceptor tyrosine-based inhibitory motif. This motif directly associates with deactivating phosphatases in its cytoplasmic part, suggesting an inhibitory signalling function. [1] [2] [3] Evidence from three different species suggests that DCIR is an important etiological factor in arthritis. First, both arthritis and autoimmunity in the rat associates with a gene complex encoding C-type lectin-like receptors, including several copies of rat DCIR. 4, 5 Second, genetic variations in the corresponding human gene complex, including DCIR, associate with the risk of developing rheumatoid arthritis (RA). 4 This association is restricted to anti-citrullinated protein antibodies (ACPA)-negative disease. Third, it was recently reported that DCIR knockout mice develop spontaneous sialadenitis and enthesitis associated with elevated serum autoantibodies indicating that DCIR indeed is a crucial negative regulator for autoimmunity. 6 Against this background, it is of interest to investigate how genetic variations could influence different structural and functional features of DCIR.
The human DCIR gene comprises of, at least, six exons and has four known transcripts, denoted by us as DCIR_v1, DCIR_v2, DCIR_v3 and DCIR_v4 2,7,8 where exons 2 and 3 are excluded in different combinations. Exon 2 includes the major part of the transmembrane domain, while in exon 3, there is a motif suggested to be responsible for the oligomerization of C-type lectin receptors. 7, 9, 10 However, all previous studies have been based on the use of anti-DCIR antibodies with similar specificity and without consideration of existence of possible DCIR isoforms. To date, no systematic study of different DCIR isoforms, including potentially soluble isoforms, have been performed. It is also unknown whether and how different genetic variants influence the expression of various forms of DCIR, and how such expression is regulated by inflammatory stimuli.
To delineate the role of genetic variants in DCIR and their association to the human inflammatory conditions, we have performed expression analyses of DCIR mRNA isoforms in autoimmune RA patients and in healthy controls.
Results

Expression of DCIR isoforms
Detection of the DCIR isoforms was initially addressed through a semi quantitative reverse transcription PCR (RT-PCR) performed in all 44 patients and all 44 controls. Transcripts were amplified using the same primer pair with the 5 0 primer in exon 1 and 3 0 primer in exon 6. We could determine that the background expression of DCIR in peripheral blood mononuclear cells (PBMCs) was characterized by different levels of isoforms DCIR_v1 to DCIR_v4 with dominance of DCIR_v1. This phenomenon is demonstrated in Figure 1a . Unstimulated PBMCs from almost all analyzed individuals demonstrated detectable levels of the DCIR isoforms. However, some patients and controls expressed very low levels.
A comparison of the expression levels of transcripts with real-time RT-PCR data between all patients and controls revealed no significant difference between the two groups ( Figure 2 ). IFN-g stimulation did not affect the relationship of mRNA expression levels or the ratio of expression between patients and controls.
Still, when stimulating with IFN-g, a general downregulation of DCIR was exhibited and certain transcripts were hardly detectable after induction (Figure 1 ). For patients and controls this downregulation was significant for all isoforms (v1: 0.49-fold, Po0.0001, v2: 0.43-fold, P ¼ 0.0175, v3: 0.2-fold, Po0.0001, v4: 0.69-fold, P ¼ 0.0007, Wilcoxon signed-rank, Figure 3 ). This downregulation of DCIR expression after IFN-g stimulation was of the same magnitude for both patients and controls when analyzed separately.
DCIR expression and association with common genetic variations Association analysis was performed in patients who were genotyped for 19 SNPs in the DCIR gene region (spanning 36 kb upstream to 20 kb downstream of DCIR). After an initial linkage disequilibrium (LD) analysis in patients, six SNPs were selected as the most informative, and were also genotyped in the healthy controls. Figure 4 demonstrates the association level for the six SNPs with the expression of DCIR_v1, DCIR_v2, DCIR_v3 and DCIR_v4 in relation to exon-intron structure of DCIR and to the LD in the region. 4 A group of five SNPs, which belong to the same recombination block, demonstrated a high level of association with DCIR_v4 expression. Analysis of association between expression and genotype was also performed separately for controls with SNPs from the block of high association with comparable results.
This association is seen as similar expression levels for individuals of same genotype. For example, data from both patients and healthy controls revealed that individuals with the TT genotype of SNP rs2024301 had significantly lower levels of the transcript DCIR_v4 in comparison with data from genotype AT and AA (patients P ¼ 0.0009, controls P ¼ 0.0078 and combined samples P ¼ 6.48 Â 10 À6 , Kruskal-Wallis, Figure 5 ). Other SNPs in high LD with rs2024301 showed consistently lower expression of DCIR_v4 for minor allele homozygotic genotype.
For validation of our finding, we repeated the association of genotype and expression in two independent and unstimulated study populations. In 20 patients with asthma and 20 controls, we could replicate our results (patients and controls for rs2024301 and DCIR_v4 P ¼ 0.002). In a smaller data set of joint biopsies from 10 RA patients, we could see the same tendency but with no statistical support.
Furthermore, we assessed the correlation between the level of DCIR expression in patients and several common Differential expression of DCIR M Ronninger et al RA disease phenotypes. However, in our material, we did not find a correlation between DCIR expression and shared epitope alleles (HLA-DRB1), rheumatoid factor or ACPA status (data not included). Also, neither of the DCIR isoforms was correlated to disease activity (DAS28) and no difference in expression was observed when stratifying by gender.
A novel transcript
In addition to the known mRNA isoforms DCIR_v1-DCIR_v4, we detected a new short isoform in 11 out of 88 analyzed samples (12.5%) defined by us as DCIR_v5 (Figure 1b) . The transcripts were sequenced separately from one individual, and we found that the novel transcript lacks exons 3 and 4, where exon 4 is a part of the predicted lectin domain. The sequence has been submitted to GenBank, accession number EU196761.
Discussion
We provide evidence for association of common variations in DCIR with expression levels of DCIR transcripts. We also determined significant downregulation of the expression of the DCIR transcripts by the proinflammatory cytokine IFN-g. However, the extent of this The influence of genotypes in the DCIR region on the expression of each of the DCIR transcripts is represented by the curves. The approximate position of the DCIR exons relative to SNPs is illustrated on top. The diagram shows the negative logarithm of the P-value for the association of SNPs with the mRNA expression of DCIR transcripts in patients without IFN-g stimulation. SNPs previously associated to RA are marked with *. The association is calculated using a codominant model and the nonparametric Kruskal-Wallis test. In the bottom panel, a linkage disequilibrium map built from the 19 selected SNPs by the software Haploview is presented. DCIR, dendritic cell immunoreceptor; IFN-g, gamma-interferon; RA, rheumatoid arthritis; SNPs, single nucleotide polymorphisms.
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M Ronninger et al downregulation was independent on genotype ( Figure 5 ). As DCIR has previously been suggested to be involved in transduction of signals that inhibit cellular activation, 1, 2, 7 our present data indicate a new mechanism, whereby genetic polymorphisms may affect immune functions by shifting the ratio of expression between different isoforms. Individuals with different DCIR genotypes thus express different patterns of DCIR products, which will lead to individual variation in immune responses. Our example also shows how splicing-related variations could be identified by fine mapping and combination with expression analysis, which links findings in association studies with certain biological function.
In this study, we investigated the relationship between variations in six DCIR-related SNPs and expression patterns of DCIR transcripts. The fact that the region is in high LD obviously makes it difficult to identify which genetic variation is the primary cause of differences in expression patterns. Nevertheless, some interesting features are discernible. It was evident that different genetic variants were associated with different total levels of expression of certain DCIR transcripts (Figure 4 ) and the IFN-g stimulation did not considerably alter the balance in the expression of DCIR transcripts (Figure 2 ). The replication of the association in the independent study population of 40 non-RA individuals (20 patients with asthma and 20 healthy controls) further confirms this genetic influence.
The downregulation by IFN-g of all DCIR transcripts in similar proportion showed no correlation to genotype or other common disease phenotypes. This indicates that these transcripts are likely under the same promoter regulation and that the stimulation of IFN-g does not significantly affect splicing mechanisms.
The difference in DCIR expression is associated with rs2024301, one of the strongest candidates in association with RA. The protective allele (TT) is associated with less expression of DCIR_v3 and DCIR_v4. This SNP is located at the start of exon 2 in the DCIR gene. The differences in expression are only significantly associated with the expression of DCIR_v3 and DCIR_v4, which might suggest that rs2024301, or another genetic variation in strong LD, alters a splicing factor motif. It has been shown that immune-stimulating factors are able to alter the balance of the expression of DCIR transcripts, for example, in neutrophils stimulated with granulocyte-macrophage colony-stimulating factor, IL-3, IL-4 or IL-13, the most abundant transcript is DCIR_v2.
7 rs2024301 is positioned 25 nucleotides into exon 2 and could function as an exonic splicing enhancing/silencing factor. By using Rainbow, a software for splicing factor prediction (http://www.ebi. ac.uk/asd-srv/wb.cgi), we found motifs for hnRNP.E1E2, hnRNP.I and hnRNP.K in this region, which suggest that this SNP might be involved in splicing repression, 11 and also SRp55 and ASF/SF2, which conversely suggest that the polymorphism rs2024301 is part of a splicing enhancer. [12] [13] [14] This does not give us conclusive information about causal variation, but build up a solid background for further vector-based analysis of the region is needed, for example, by using minigene constructs. 15, 16 The difference between patients and healthy controls in expression is not as evident as the change associated with genotype. This possibly illustrates the more general importance of the DCIR for inflammatory or autoimmunity-related reactions rather than RA-specific mode of function. Also, the replication of the association in an independent material with asthma patients and controls supports this. However, the data have to be interpreted with caution due to obvious heterogeneity in the human material in our study. The problem could be circumvented by stratifying for disease subsets, for instance by ACPA and rheumatoid factor (RF) status, or human leukocyte antigen genotype but with the obvious drawback of decreasing sample size. With a limited sample size, we may not have enough power to recognize fine differences in the groups.
Detection of a new splicing isoform in 12.5% of individuals involved in our study represents further illustration of heterogeneity of the expression of human genes. It is obvious that usual screening of the splicing isoforms is restricted in such studies due to fewer numbers of samples. However, regarding protein isoforms, more analysis is pending due to the relatively poor spectrum of commercially available antibody specificities. We only found evidence for two DCIR protein isoforms in published sources 2 and a more systematic approach for isoform detection may face the problem of low expression rate or rare expression of certain isoforms, which may, nonetheless, be physiologically important. In most illustrative cases, such common Differential expression of DCIR M Ronninger et al differences may shift a balance in splicing isoforms with an opposite function, which may have pathological consequences. 17 We have used two PCR-based techniques for detection of DCIR transcripts, which give a certain advantage for analysis. The use of one primer pair for amplifying several isoforms gives advantages in simultaneous visualization of all transcripts and this also led us to the finding of a completely novel transcript.
Our paper provides both methods and incitement for the determination of DCIR isoforms in different contexts, and in different cell types, including cell types not previously known to express DCIR, such as the DCIR þ T-cell subpopulations that were recently discovered in human rheumatic joints. 18 In conclusion, our data demonstrate the influence of common variations on the transcription of the DCIR gene, which we also have replicated in an independent material. This indicates the significance of DCIR in immune reactions regulated by IFN-g and related to the development of inflammation.
Materials and methods
Study population
Rheumatoid arthritis patients fulfilled the American College of Rheumatology 1987 criteria 19 and there were no major differences in type of therapy within the group. Healthy controls, from the same population (Swedish Caucasians) were selected to match the patients by gender and roughly by age (differenceo10 years).
Cell culture
Peripheral blood mononuclear cells from 44 RA patients and 44 healthy controls were separated from whole blood in citrate tubes (Vacutainer, Becton-Dickinson, Franklin Lakes, NJ, USA) and washed in phosphate buffered saline. The concentration was determined with Turkey blue (viability of cells was initially checked with Trypan blue) and 5*10 5 cells was cultivated for 6 h at 37 1C with 5% CO 2 in medium Dulbecco's modified Eagle's medium (DMEM), fetal calf serum (FCS), penicillin/streptomycin, L-glutamine, 2-betamercaptoethanol, pyruvic acid) with or without 50 units of IFN-g (Preprotech, London, UK).
RNA and cDNA preparation Total RNA was isolated from PBMCs according to the manufacturer's protocol (RNeasy Mini, Qiagen, Hilden, Germany) and cDNA synthesized (Superscript RNase HReverse Transcriptase, Invitrogen (Carlsbad, CA, USA); RNAguard RNase Inhibitor (porcine), GE Healthcare, Piscataway, NJ, USA; Random primers, Invitrogen, GeneAmp dNTP mix, Applied Biosystems, Warrington, United Kingdom).
PCR and real-time PCR
A primer pair for semi-quantitative PCR was designed in the first and the last known exons of the DCIR gene (forward 5 0 -TTCAAAAATGAATTCAAGTCCTCAG-3 0 , reverse 5 0 -TGATTTACGAAAATTTAGCACAACG-3 0 ), covering all the known transcripts since these exons are constitutive. The enzyme used for PCR reaction was AmpliTaq Gold together with GeneAmp dNTP Mix with dTTP (Applied Biosystems, Branchburg, NJ, USA).
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used to normalize cDNA samples (forward 5 0 -AGGGCTGCTTTTAACTCTGGTAAA-3 0 , reverse 5 0 -CAT ATTGGAACATGTAAACCATGTAGTTG-3 0 ). Evaluation of PCR products were performed with the precast polyacrylamide gel electrophoresis system, Novex Xcell (San Diego, CA, USA), was used (20% TBE Gel, 1.0 mm Â 15 well, Invitrogen, Carlsbad, CA, USA). Silver staining was used for visualization of bands (GE Healthcare, Uppsala, Sweden). The gels were digitalized using the Kodak EDAS 290 system and intensity was measured with Kodak 1D software. Individual transcripts were assessed with transcript-specific RT-PCR primers (positioned over exon boundaries), which were used with SYBR Green dye (iTaq SYBR Green Supermix with ROX, Bio-Rad, Hercules, CA, USA) in duplicate and measured using an ABI 7900 and 384-well plates. The expression data were measured relative to an mRNA standard from a dendritic cell line and adjusted with GAPDH with the same primers as used for semiquantitative PCR. Primers for DCIR_v1 forward 5 0 -CCCTCACAAAAGTAATACCGGATT, reverse 5 0 -GAAC CAGCTCTTTTGTAGTCTTTTTTTC and primers for DCIR_v4 forward 5 0 -CACAGCCTCTTCTGCAGAGACA, reverse 5 0 -CCATTCTAGCACAGTCCTTCTCACT. All calibration curves had r 2 values over 0.99 and the efficiency for DCIR_v1 was 90%, DCIR_v2 99%, DCIR_v3 95% and for DCIR_v4 106%.
Genotyping by TaqMan and dynamic allele-specific hybridization (DASH) TaqMan allelic discrimination (5 0 nuclease assay) was performed according to an Applied Biosystems standard protocol. Assay design and quality control was provided by Applied Biosystems Inc. Genotyping was performed using 384-format and 7700HT GeneAnalyser (Applied Biosystems, USA) with end point measurement after 35 cycles.
Dynamic allele-specific hybridization was performed as described previously. [20] [21] [22] Two PCR primers and one DASH probe per target SNP were designed by means of custom DFold software 23 provided by DynaMetrix Ltd (Stockholm, Sweden). These oligonucleotides were provided and AQHPLC-purified by GmbH (Sö flingon, Germany). Owing to logistics, the first nine markers were genotyped by DASH for 1285 RA cases and 709 healthy controls (rs2889626, rs1062836, rs2024301, rs2377422, rs4573763, rs7302963, rs10840759, rs4604965 and rs6486850), 4 while the next 10 markers were genotyped by TaqMan for 1889 RA cases and 1069 healthy controls (rs7305412, rs2889629, rs2024304, rs2110067, rs1035060, rs11043498, rs4322490, rs1133104, rs4589367 and rs6486851). The SNPs rs1133104, rs4573763, rs7302963 and rs4604965 were genotyped both by TaqMan and DASH. This data was used for LD plot in Figure 4 .
Genotyping of SNP rs1133104 by PCR and Nsp I cleavage Primers were designed using the Primer3 software (Rozen 2000). Forward 5 0 -GCCGGAAATGCAGATGGA GGAGAAGCTACATGCTGA; reverse 5 0 -AACCAGATA AAAATTAAGGGAGGCTCATGTTCTCTAC. Amplification was performed using a GeneAmp PCR system 9600 (PerkinElmer, Norwalk, CT, USA) with a three-step PCR protocol (94 1C for 30 s, 65 1C for 30 s and 72 1C for 1 min) .
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The PCR products were cleaved with Nsp I (New England BioLabs, Hitchin, UK), and the cleaved PCR products were run in 20% acrylamide gels (Invitrogen) and stained using a DNA Silver Staining Kit (Amersham Biosciences, Uppsala, Sweden). Allele T in SNP rs1133104 is located in one of Nsp I restriction sites. The cleaved PCR product contains allele T and the intact product contains allele G.
Sequencing
To validate and find more transcripts, gel PCR products were isolated and purified with a cleanup kit (Qiagen) followed by sequencing (MWG, www.mwg-biotech.com).
Products that had too few copies to be directly assessed were instead cloned into a vector according to a recommended protocol (TOPO TA Cloning kit with pCR 2.1-TOPO, Invitrogen). The vectors were transfected into competent Escherichia coli, which were incubated overnight at 37 1C on agar plates (Bacto-tryptone, Bacto-yeast, NaCl, Bacto-agar, Ampicillin) and then colonies positive for the vector insert were screened with the same primers used for the original PCR for selecting colonies with interesting inserts. Interesting colonies were used for plasmid DNA preparation using the manufacturer's protocol (Qiagen miniprep, Hilden, Germany), which were sequenced (MWG-Biotech AG, Ebersberg, Germany).
Statistical evaluation
Effect on DCIR expression by IFN-g was statistically calculated with the Wilcoxon signed-rank test. The test does not require the assumption of the underlying data distribution. Data are treated pairwise where each pair consists of a measurement of the DCIR expression with and without stimulation by IFN-g. Expression distribution differences for patients and controls were analyzed by the Mann-Whitney U test (nonparametric).
Association of expression with genotypic variants was analyzed in a codominant model, creating three categories of each genotype. Kruskal-Wallis was used as the statistical test (nonparametric).
Genetic identifiers DCIR is also known as CLEC4A, CLEC6SF and LLIR and has the Ensembl identifier ENSG00000111729. The DCIR transcripts have the following identifiers in Ensembl and Entrez, respectively: DCIR_v1 ENST00000229332, NP_057268.1; DCIR_v2 ENST00000352620, NP_919432.1; DCIR_v3 ENST00000360500, NP_919429.2; DCIR_v4 ENST00000345999, NP_919430.1.
